Evidence map›Paper›PMID 41174063›Full record

ArticleScientific reports2025

Multi-omic analysis reveals elevated BRI3BP expression associated with hepatocellular carcinoma progression and poor prognosis.

Ling Liu, Ye Wang, Jintao Zheng, Lixin Zhou, Chenao Yang, Jiachen Zhang, Changku Jia

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ling LiuDepartment of Hepatobiliary and Pancreatic Surgery, Hangzhou First People's Hospital Affiliated to Medical School of Westlake University, No.261 Huansha Road, Shangcheng District, Hangzhou, 310006, Zhejiang, China.
Ye WangDepartment of Hepatobiliary and Pancreatic Surgery, The Fourth School of Clinical Medicine, Zhejiang Chinese Medical University, No.970 Puyan Road, Binjiang District, Hangzhou, 310053, Zhejiang, China.
Jintao ZhengDepartment of Hepatobiliary and Pancreatic Surgery, The Fourth School of Clinical Medicine, Zhejiang Chinese Medical University, No.970 Puyan Road, Binjiang District, Hangzhou, 310053, Zhejiang, China.
Lixin ZhouDepartment of Hepatobiliary and Pancreatic Surgery, Hangzhou First People's Hospital Affiliated to Medical School of Westlake University, No.261 Huansha Road, Shangcheng District, Hangzhou, 310006, Zhejiang, China.
Chenao YangDepartment of Gastroenterological Surgery, Hangzhou First People's Hospital Affiliated to Medical School of Westlake University, No.261 Huansha Road, Shangcheng District, Hangzhou, 310006, Zhejiang, China.
Jiachen ZhangDepartment of Hepatobiliary and Pancreatic Surgery, The Fourth School of Clinical Medicine, Zhejiang Chinese Medical University, No.970 Puyan Road, Binjiang District, Hangzhou, 310053, Zhejiang, China.
Changku JiaDepartment of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital, School of Medicine, Zhejiang University, No.88 Jiefang Road, Shangcheng District, Hangzhou, 310009, Zhejiang, China. jiachk@126.com.

Funding

Hangzhou Health Science and Technology Plan Project A20200526The Construction Fund of Key Medical Disciplines of Hangzhou 2025HZGF05Zhejiang Traditional Chinese Medicine Science and Technology Plan Project 2022ZB275
6 · The paper itself

Abstract

BRI3BP, an RNA-binding protein upregulated in multiple cancers, plays an undefined role in hepatocellular carcinoma (HCC). This study investigates its diagnostic and prognostic potential in HCC. Multi-omics analysis of TCGA and GEO data identified BRI3BP-interacting genes and enriched pathways. Genomic and epigenetic alterations were assessed using cBioPortal and MethSurv. Immune infiltration was profiled via ssGSEA and TIMER 2.0. Prognostic relevance was validated through survival analysis, Cox regression, and experimental assays. BRI3BP was overexpressed in HCC and correlated with advanced tumor stage, shorter overall survival (OS), and disease-free survival (DFS). Functional enrichment linked BRI3BP to cell cycle regulation, Rho GTPase activity, and copper homeostasis. Analysis of transcriptomic data revealed that BRI3BP expression also significantly correlated with immune cell infiltration and an immunosuppressive microenvironment, validated by immunohistochemistry showing reduced CD8 + and increased CD68 + cells in high-BRI3BP samples. In vitro, BRI3BP overexpression promoted HCC cell migration and invasion and activated the ROCK signaling pathway, suggesting potential involvement in tumor progression. Drug sensitivity assays confirmed lower lapatinib IC50 in overexpression models. High BRI3BP expression correlates with aggressive HCC phenotypes, poorer survival, and dysregulated oncogenic pathways, supporting its role as a prognostic biomarker and candidate therapeutic target.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsRNA-Binding ProteinsBiomarkers, TumorCell Line, TumorCell MovementDisease ProgressionFemaleGene Expression Regulation, NeoplasticHumansMaleMultiomicsPrognosisTumor MicroenvironmentBiomarkers, TumorRNA-Binding ProteinsBRI3BPCuproptosisHepatocellular carcinomaImmune infiltrationPrognostic biomarker

Identifiers

PMID41174063
PMCPMC12578974

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.